Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction
|ClinicalTrials.gov Identifier: NCT00576121|
Recruitment Status : Withdrawn
First Posted : December 18, 2007
Last Update Posted : June 23, 2016
|Condition or disease|
|Acute Myocardial Infarction|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||August 2011|
|Estimated Study Completion Date :||August 2012|
Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
- To predict left ventricular remodeling after myocardial infarction using serum matrix metalloproteinase measurement with Tl201 SPECT/CT hybrid imaging and MRI. [ Time Frame: 1 day ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00576121
|United States, Connecticut|
|Yale New Haven Hospital|
|New Haven, Connecticut, United States, 06520|
|Principal Investigator:||Albert J Sinusas, MD||Yale University|